21CC Cancer Intelligence (Issue 47): Reindeer Bio/Xinda Bio BCMA Targeted CAR-T Therapy Approved for Market Launch; The latest phase 3 test results of AstraZeneca HIMALAYA are positive

Tech 2023-07-03 22:16:40 Source: Network

21CC(cancercare)2121CC//BCMACAR-T630NMPABBCMACAR-TMM3BCMACAR-TCT103AIBI326BCMACAR-TTCARscFvCD8a4-1BBCD3NMPAFDA/20232FDA/NMPA20226628NMPArepotrectinibROS1Rafael AmadoROS15CDEROS16281ALKNSCLCWX-0593ALK/ROS1ALKALKROS1WX-0593ALKROS1NSCLC180mgIIALK1469.390412056IRCORR67

21CC(cancercare)2121CC

/

/BCMACAR-T

630NMPABBCMACAR-TMM3BCMACAR-T

CT103AIBI326BCMACAR-TTCARscFvCD8a4-1BBCD3NMPAFDA/20232FDA/

NMPA20226

628NMPArepotrectinibROS1

Rafael AmadoROS1

5CDEROS1

6281ALKNSCLC

WX-0593ALK/ROS1ALKALKROS1WX-0593ALKROS1NSCLC180mg

IIALK1469.390412056

IRCORR67.8%DCR96.6%ORR61.6%DCR94.5%DoR13.1PFS/TTP14.41881.9%

NSCLC

627RETNMPARETNSCLC

ARROWI/IIRETNSCLCRET

627HR2HER2

1CDK4/6

CDK4/6Ibrance20152FDAHRHER220162HRHER2Palbociclib20187PalbociclibHRHER2

EvaluatePharma202288.7Insight57.95%

CAR-T

626NMPACDE12Br/r LBCL

2017Gilead SciencesKite PharmaYescartaAxicabtagene CiloleucelCD19CAR-TCAR-TTT

//

LumakrasNSCLC IIIK

627IIICodeBreaK 202sotorasibLumakrasKIVIIIB/CNSCLC

750PD-L1KRAS p.G12CNSCLCPFS20239203011

SotorasibCarmot TherapeuticsKRAC G12CIIICodeBreaK 20020215FDAKRAS G12CNSCLCCodeBreaK 200PD-1/PD-L1NSCLCsotorasibKKPD-L1NSCLC

HIMALAYA3

630AstraZenecaHIMALAYA34ImjudotremelimumabImfinzidurvalumabOS

82657%

ImfinziPD-L1PD-L1PD-1CD80FDAImjudoCTLA-4CTLA-4T

ImfinziImjudoSTRIDESingle Tremelimumab Regular Interval DurvalumabImjudo300 mgImfinzi1500 mgImfinzi3HIMALAYA10

III

630IIIGEMSTONE-3042023ESMO (ESMO GI 2023)

GEMSTONE-304IIIFP+BICRPFSOSPFSBICRORRDoR

2022107PFSOSGEMSTONE-304BICRPFSOS

6291167.HKJCA-AACRJCA-AACR Precision Cancer Medicine International ConferenceKRAS G12CJAB-21822KRAS G12C

33.3%11/3390.9%30/33mPFS6.962.8%27/4393%40/432023523TARE1-2

553%KRAS G12CKRAS G12C

RDCI

627(RDC) TLX250-CDx (89Zr-TLX250)(ccRCC)I

TLX250-CDxII10/(PET/CT)

TLX250-CDx ccRCC RDC IX (CA9)CA9 ccRCC ccRCCTLX250-CDx FDA

ADC

626PD-1MSLN ADC RC88 c-METADCRC108

I/IIaRC88RC108

PD-1 PD-1

RC88MSLNADC201811RC88MSLN

RC108c-METADC202011c-MetRC108c-MET

629(IARC)(JECFA)714

5 WHO

6 29 ICBA

21APP

Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])

Mobile advertising space rental

Tag: Bio 21CC Cancer Intelligence Issue Reindeer Xinda BCMA Targeted